Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.Scientific reports · 2016
   Trial
2. Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.Journal of personalized medicine · 2024
   Review
3. Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024
   Review
4. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.Exploration of targeted anti-tumor therapy · 2023
   Review
5. Dynamic Meta-data Network Sparse PCA for Cancer Subtype Biomarker Screening.Frontiers in genetics · 2022
   Article
6. ROS1 Targeted Therapies: Current Status.Current oncology reports · 2021
   Review
7. Ocular Toxicity of Targeted Anticancer Agents.Drugs · 2021
   Review
8. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.Archives of medical research · 2021
   Review
9. Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor.Diabetology international · 2021
   Article
10. Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.Journal of drug assessment · 2018
    Article
11. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.